Invention Grant
![[1,3]oxazines](/docs/US/2015-07-07/US09073909B2/abs.jpg.600x600.jpg)
- Patent Title: [1,3]oxazines
- Patent Title (中): [1,3]恶嗪
-
Application No.: US14118754Application Date: 2012-06-04
-
Publication No.: US09073909B2Publication Date: 2015-07-07
- Inventor: Edilio Boroni , Luca Gobbi , Hans Hilpert , Michael Honer , Dieter Murl , Robert Narquizian , Alessandra Polara
- Applicant: Edilio Boroni , Luca Gobbi , Hans Hilpert , Michael Honer , Dieter Murl , Robert Narquizian , Alessandra Polara
- Applicant Address: US NJ Nutley
- Assignee: HOFFMANN-LA ROCHE INC.
- Current Assignee: HOFFMANN-LA ROCHE INC.
- Current Assignee Address: US NJ Nutley
- Priority: EP11168953 20110607
- International Application: PCT/EP2012/060476 WO 20120604
- International Announcement: WO2012/168175 WO 20121213
- Main IPC: C07D413/12
- IPC: C07D413/12 ; C07D265/06 ; A61K31/535 ; A61K31/5355
![[1,3]oxazines](/abs-image/US/2015/07/07/US09073909B2/abs.jpg.150x150.jpg)
Abstract:
The present invention provides compounds of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes. The invention further provides a radio-labelled derivative thereof.
Public/Granted literature
- US20140112867A1 [1,3]OXAZINES Public/Granted day:2014-04-24
Information query
